Drug intelligence / Profile preview

salbutamol + budesonide

Development stage
Approved
Lead developer
AstraZeneca
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Inhalation
01

Overview

Salbutamol + budesonide is a fixed-dose combination inhalation medication used for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in adults. It combines two active ingredients: salbutamol (also known as albuterol), a short-acting beta2-adrenergic agonist bronchodilator that relaxes airway smooth muscle, and budesonide, an inhaled corticosteroid that reduces inflammation in the airways. This combination is notable for being the first product containing an inhaled corticosteroid approved by the FDA as a reliever (rescue) therapy rather than solely as a controller medication for asthma. The drug is administered via oral inhalation using a metered-dose inhaler[1][2][3][5][6].

Brand names
Airsupra
Other names
albuterol and budesonidesalbutamol/budesonide
02

Targets

GR (Glucocorticoid receptor)ADRB2 (β2)

Beyond the preview

Go deeper on salbutamol + budesonide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on salbutamol + budesonide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call